a Custom Oligonucleotide Synthesis Business located in Gaithersburg, MD.With this acquisition, Orochem will become a significant player in the customoligo synthesis market having already been supporting oligonucleotidesynthesis establishment with several products that range from synthesis platesto CPG (controlled pore glass) columns as well as having proprietarytechnologies for the purification of small and large scale oligonucleotides."We saw great synergy between the Orochem and Oligonet products and thisacquisition helps us offer a complete line of products to our customers," saidDr. The company's core expertise is in the development of customizedindividual and high throughput Sample Preparation tools that span liquidhandling, parallel synthesis, parallel purification, and parallel processing.For further information visit Technologies Inc.Dr. Ravi Vinayak, +1-650-996-4951, for Orochem Technologies Inc.. VANCOUVER, BRITISH COLUMBIA, Jun 25 (MARKET WIRE) -- Midway Gold Corp. (TSX VENTURE: MDW)(NYSE Amex: MDW) ("Midway") ispleased to announce a Mineral Resource estimate for the Golden EagleProject, Washington. Using a 0.020 ounce per ton (opt) gold cut-off, theIndicated resource is 31.9 million tons grading 0.055 opt gold,containing 1.769 million ounces of gold. There is an additional Inferredresource of 5.1 million tons grading 0.038 opt gold, containing 194,000ounces of gold.
This estimate is based on historic exploration primarilyby Hecla Limited and Santa Fe Pacific Gold."This new resource at Golden Eagle represents a significant increase inthe mineral resource base controlled by the company," said Alan Branham,President and CEO of Midway Gold Corp. "An independent review of themetallurgical testing shows favorable gold recovery using refractory oretreatments. Midway's next step is to conduct a scoping level study, whichwill complete a preliminary economic assessment of the resource. The most likely cut-off grade for this deposit is not known at this time and must be confirmed by the appropriate economic studies.2. Tons and ounces have been rounded and this may result in minor discrepancies in the totals.3. The estimated metal content does not include any consideration of mining, mineral processing, or metallurgical recoveries.Extensive metallurgical work by Hecla Limited and Santa Fe PacificGold between 1989 and 1997 was reviewed and summarized by Dr Thom Seal(PhD, PE) of Differential Engineering Inc for estimated optimal goldrecoveries. According to this independent review, three potentialprocessing options exist for the Golden Eagle refractory ore.
Theseinclude whole-ore bio-oxidation, flotation, or pressure oxidationtreatments, with recoveries ranging from 75-94%. All three processesdemonstrate the potential for good gold recoveries. These results havenot yet been verified by Midway test work nor have the economics of eachprocess been reviewed."In general, the reviewed previous metallurgical reports, if verified asrepresentative of the Golden Eagle project, indicate that the depositrepresents a refractory gold ore target with the material types and gradesimilar to some of the gold ore processed from the Carlin Trend inNevada. The processing options identified in the metallurgical reviewshow that the project has potential for economic gold recovery within thereviewed parameters and current gold price environment," said Dr.
It was conductedunder the supervision of Eric Chapman (M.Sc., C.Geol), Snowden MiningIndustry Consultants Inc. and Thom Seal (PhD, PE), Principal andMetallurgist, Differential Engineering Inc. who are the Qualified Personsresponsible for the technical report.The current resource estimate includes verified drill results from 222historic holes that were available up to May 1, 2009. Verification wascompleted by comparison of gold values to laboratory certificates anddrill logs obtained from historic operators of the project. Only goldvalues that had laboratory certificates or drill log verification wereused in the resource estimate. Mineralized domains were established byinterpretation of geological, structural and assay information onsections and plans.
